Harrow (HROW) EBITDA Margin Growth (3y) (2016 - 2026)
Harrow (HROW) EBITDA Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 1,673.00 |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -37.00 |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -5,395.00 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -1,442.00 |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -1,299.00 |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 5,091.00 |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 5,193.00 |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn | -5,459.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,459.00 |
| Dec 31, 2025 | 2,625.00 |
| Sep 30, 2025 | 2,100.00 |
| Jun 30, 2025 | 1,065.00 |
| Mar 31, 2025 | -3,298.00 |
| Dec 31, 2024 | 2,799.00 |
| Sep 30, 2024 | 2,255.00 |
| Jun 30, 2024 | -1,986.00 |
| Mar 31, 2024 | -3,892.00 |
| Dec 31, 2023 | -3,140.00 |
| Sep 30, 2023 | -600.00 |
| Jun 30, 2023 | 4,685.00 |
| Mar 31, 2023 | 995.00 |
| Dec 31, 2022 | -1,609.00 |
| Sep 30, 2022 | 3,407.00 |
| Jun 30, 2022 | 1,292.00 |
| Mar 31, 2022 | 1,402.00 |
| Dec 31, 2021 | 1,031.00 |
| Sep 30, 2021 | -1,382.00 |
| Jun 30, 2021 | 2,900.00 |